Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases.

HIPEC KRAS colorectal cancer (CRC) cytoreductive surgery (CRS) peritoneal metastases (PM)

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
12 Apr 2024
Historique:
received: 20 12 2023
revised: 17 02 2024
accepted: 29 02 2024
medline: 14 4 2024
pubmed: 14 4 2024
entrez: 13 4 2024
Statut: aheadofprint

Résumé

There is little evidence on KRAS mutational profiles in colorectal cancer (CRC) peritoneal metastases (PM). This study aims to determine the prevalence of specific KRAS mutations and their prognostic value in a homogeneous cohort of patients with isolated CRC PM treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Data were collected from 13 Italian centers, gathered in a collaborative group of the Italian Society of Surgical Oncology. KRAS mutation subtypes have been correlated with clinical and pathological characteristics and survival [overall survival (OS), local (peritoneal) disease-free survival (LDFS) and disease-free survival (DFS)]. KRAS mutations occurred in 172 patients (47.5%) out of the 362 analyzed. Two different prognostic groups of KRAS mutation subtypes were identified: KRAS In patients with CRC PM, different KRAS mutation subgroups can be determined according to specific codon substitution, with some mutations (KRAS

Sections du résumé

BACKGROUND BACKGROUND
There is little evidence on KRAS mutational profiles in colorectal cancer (CRC) peritoneal metastases (PM). This study aims to determine the prevalence of specific KRAS mutations and their prognostic value in a homogeneous cohort of patients with isolated CRC PM treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
MATERIALS AND METHODS METHODS
Data were collected from 13 Italian centers, gathered in a collaborative group of the Italian Society of Surgical Oncology. KRAS mutation subtypes have been correlated with clinical and pathological characteristics and survival [overall survival (OS), local (peritoneal) disease-free survival (LDFS) and disease-free survival (DFS)].
RESULTS RESULTS
KRAS mutations occurred in 172 patients (47.5%) out of the 362 analyzed. Two different prognostic groups of KRAS mutation subtypes were identified: KRAS
CONCLUSIONS CONCLUSIONS
In patients with CRC PM, different KRAS mutation subgroups can be determined according to specific codon substitution, with some mutations (KRAS

Identifiants

DOI: 10.1016/j.esmoop.2024.102976 PMID: 38613907
pubmed: 38613907
pii: S2059-7029(24)00744-0
doi: 10.1016/j.esmoop.2024.102976
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102976

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

M Tonello (M)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua.

D Baratti (D)

Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

P Sammartino (P)

Cytoreductive Surgery and HIPEC Unit, Department of Surgery 'Pietro Valdoni', Sapienza University of Rome, Rome.

A Di Giorgio (A)

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli, Rome.

M Robella (M)

Surgical Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin.

C Sassaroli (C)

Integrated Medical Surgical Research in Peritoneal Surface Malignancy, Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Pascale IRCCS, Naples.

M Framarini (M)

General and Oncologic Department of Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì.

M Valle (M)

Peritoneal Tumours Unit, IRCCS, Regina Elena Cancer Institute, Rome.

A Macrì (A)

Peritoneal and Retroperitonel Surgical Unit-University Hospital 'G. Martino' Messina.

L Graziosi (L)

General and Emergency Surgery Department, University of Perugia, Santa Maria Della Misericordia Hospital, Perugia.

F Coccolini (F)

General Emergency and Trauma Surgery, Bufalini Hospital, Cesena; General Emergency and Trauma Surgery, Pisa University Hospital, Pisa.

P V Lippolis (PV)

General and Peritoneal Surgery, Department of Surgery, Hospital University Pisa (AOUP), Pisa.

R Gelmini (R)

General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia.

M Deraco (M)

Peritoneal Surface Malignancy Unit, Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

D Biacchi (D)

Cytoreductive Surgery and HIPEC Unit, Department of Surgery 'Pietro Valdoni', Sapienza University of Rome, Rome.

M Aulicino (M)

Surgical Unit of Peritoneum and Retroperitoneum, Fondazione Policlinico Universitario A. Gemelli, Rome.

M Vaira (M)

Surgical Oncology Unit, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin.

S De Franciscis (S)

Colorectal Surgical Oncology, Abdominal Oncology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione Pascale IRCCS, Naples.

F D'Acapito (F)

General and Oncologic Department of Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forlì.

F Carboni (F)

Peritoneal Tumours Unit, IRCCS, Regina Elena Cancer Institute, Rome.

E Milone (E)

Peritoneal and Retroperitonel Surgical Unit-University Hospital 'G. Martino' Messina.

A Donini (A)

General and Emergency Surgery Department, University of Perugia, Santa Maria Della Misericordia Hospital, Perugia.

P Fugazzola (P)

General surgery, Fondazione IRCCS Policlinico San Matteo, Pavia.

P Faviana (P)

Department of Surgical, Medical, Molecular Pathology and Critical Area, University of Pisa, Pisa.

L Sorrentino (L)

General and Oncological Surgery Unit, AOU of Modena University of Modena and Reggio Emilia.

E Pizzolato (E)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua.

C Cenzi (C)

Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

P Del Bianco (P)

Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.

A Sommariva (A)

Unit of Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, Padua. Electronic address: antonio.sommariva@iov.veneto.it.

Classifications MeSH